FTC: drugmakers’ agreement was cover for illegal scheme

The Federal Trade Commission has argued that a 2010 agreement between Impax and Endo to develop a Parkinson’s treatment drug was a pretence for the first $10 million instalment Endo paid to keep a generic rival off the market.

Get unlimited access to all Global Competition Review content